Neuraceq FDA Approval History
FDA Approved: Yes (First approved March 19, 2014)
Brand name: Neuraceq
Generic name: florbetaben F18
Dosage form: Injection
Company: Piramal Imaging
Treatment for: Positron Emission Tomography Imaging
Neuraceq (florbetaben F18) is a radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaquedensity in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
Development timeline for Neuraceq
| Date | Article |
|---|---|
| Mar 20, 2014 | Approval FDA Approves Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Plaques |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
